PEB - Pacific Edge Ltd

[geo]

Having sold out of PEB for a healthy profit and very happy, But it was only a small part of my portfolio which I classed as a speculative buy never an investment. Anything that does not generate income is not a investment gold and silver are not, land is not unless it is leased. I probably stayed in to long but wanted to see the sales result was not impressed this company has a long way to go before it can be classed an investment.

As I have stated before cant fault the science but not sure current management is up to the task to many conflicting statements, vagueness about next product to come online, valuations to come out shortly yet to see. What this company needs is to find a large partner let them take over and pay PEB royalties. The way PEB is burning through the cash it wont be long before they are begging the shareholders for yet another capital raising. So it has a long way to go before being called an investment.

[MAC]

I just see a company moving along a development and commercialisation timeline very well, sure and steadily, confidently ticking off milestones as they go.

Pacific Edge could have sold out or gone with a US JV, this would have provided shareholders with a quick buck, but would not have rewarded shareholders nearly as well in the medium to long run.

Very often JV’s underperform in house operations, I do think they have their place though, and I think Pacific Edge are doing the right thing in Europe by entering the market through a JV, there are simply too many EU regulatory hurdles to jump to initially go it alone.

ATM are in a similar position and have taken the same approach with their Muller Wiseman JV in entering Europe, it allowed them to use existing contacts and to gain a foot hold. ATM have since bought out the JV partner and are going it alone, as now established, they are better motivated to sell and push the product themselves.

The US is a more open market, and Pacific edge have established a separate commercial company in PEDusa, perhaps we will see a PEDeurope within a couple of years too, who knows. I suspect ATM will enter the US with their own company also and we should find out anytime about now.

Fed by very high quality low cost research and development out of PEB, PEDusa could well become quite a substantial company within the biotech sector in a few years.

Patience Provides Prosperity.

[MAC]

the part of your post I have highlighted is utter crap and nothing more than ramping.
You are the first to want posters to prove with links and god not what else to support their opinions and statements....... so where is the proof that PEB could have sold out or gone with a joint venture that would have provided shareholders a quick buck.
The only thing I have seen or heard from the company is the exact opposite to what you are saying.
PEB management have openly said they have made several attempts at a JV but have been turned down.
Seems to me that PEB have had no choice but to go it alone.

There’s no need to be insulting Snapiti, that’s just unnecessary don’t you think.

I only know what Pacific Edge have told us directly, when asked at the last AGM if they had been approached by any Pharma’s, the reply provided from CS and DD whilst on the podium, was that “yes they had been approached but had managed to fend them off”.

The audience of shareholders present seemed quite satisfied with that response and there were no follow up questions raised.

[psychic]

the part of your post I have highlighted is utter crap and nothing more than ramping.
You are the first to want posters to prove with links and god not what else to support their opinions and statements....... so where is the proof that PEB could have sold out or gone with a joint venture that would have provided shareholders a quick buck.
The only thing I have seen or heard from the company is the exact opposite to what you are saying.
PEB management have openly said they have made several attempts at a JV but have been turned down.
Seems to me that PEB have had no choice but to go it alone.

Snapiti. Aside from NG's claims that PEB has been on the market, what evidence do you have? They approached Roche, then decided to go it alone. As far as I know they have not been looking for suiters - They do not want to sell!

Please make time to listen to the double shot interview, then tell me where we have this wrong. No more stupid rants eh?

http://www.youtube.com/watch?v=BE43Of1TUGY

[psychic]

This is totally insane....... approached by other pharma's for what.... a cup of tea and cake... it is just further proof of the companies rhetoric.
If the company had received a genuine take over offer this would have to go to a shareholders vote....... so who's kidding who here.

I know you are well aware that, recently, the company has clarified it's position on what has occurred so far with the process of finding a joint venture partner.
But your post clearly indicates they could of gone with a US joint venture when you know the company has just clarified this by admitting they have tried several times but were rebuffed.

Obviously not going to respond to my last post Snapiti.

Are you are saying that "the company has clarified it's position on what has occurred so far with the process of finding a joint venture partner" because a poster on here called New Guy says that this is what he thought he understood from the recent Shareholders Assn meeting?
Is that it?

[psychic]

mate, you are wasting your time here. This forum is full of some very smart and interesting people. However, many other's actually have no idea. I've been shocked over the last few months to realise just how little some people actually know/understand/listen/absorb/learn.

Don't waste your time.

HAHAHAHA. Coming from you pal that is precious

[psychic]

Actually, other posters eventually/begrudgingly confirmed that myreporting of the event was indeed accurate. Let it go psychic.

Um, no. Ill take my info from the source I think..
Disprove it

[MAC]

I think you will find that Pacific Edge and Roche had some healthy discussion very early when Cxbladder was in the research phase, when the Cxbladder product was still a lab bound concept.

The company has come a very long way since those days, put more meat on the bones, clinical trials, regulatory approvals, user programmes, more prospective products, the start of commercialisation, and we have been told more recently, less than a year ago, that they have since fended off approaches by the Pharma's.

Hancock's has clarified all this on several occasions that I can recall, but sure let's have the same discussion all over again because all forum members like to read the same posts over and over.

I think there is some confusion in the information reported from the Share Holders Association meeting; the interview with Andrew Patterson 28th October 2013 may help regarding the approaches to big pharma with the gene profile to sell under licence in the early stages of Pacific Edge (~4:45). It just shows that without validation, do not believe everything that is posted here; the delivery may distort the message.

There is some really good history about Pacific Edge in the 'Double Shot Interview with David and Andrew Patterson, I have attached a link to the full interview.

HyperLink: David Darling Double Shot Interview

[psychic]

I have absolutely no interest in covering all this material again. Nice try, though.

No , I am not interested in your recollection

I was asking you for some form of proof that PEB approached Roche (or anyone for that matter) with a view to selling or J/V , SINCE they decided to go it alone.

What is this about "being caught out before"??

[andrewm]

May 2014 study- Hematuria overlooked as a sign of bladder cancer in women.
"Only 14% of the beneficiaries who met the study criteria had a complete hematuria evaluation; 21% had incomplete examinations and 65% had none at all."
"Dr. Barocas and colleagues speculate that some primary care practitioners may assume a woman presenting with new or recurrent hematuria has a urinary tract infection and treat her empirically with antibiotics, and that this process may be repeated over several visits until the woman develops other, more serious symptoms that lead to a diagnosis of later-stage bladder cancer.
They are hesitant, however, to lay the blame at the door of their colleagues in primary care. Instead, they say, all clinicians need better tools for risk-stratifying patients for hematuria evaluations. They also urge development of collaborative efforts between urologists and primary care practitioners that emphasize the need for earlier detection of bladder cancer in women and address sex-based disparities in bladder cancer survival."
http://www.medscape.com/viewarticle/825327